Estonian president: Ukraine will become NATO member in long term
Source: Alar Karis in an interview with Lithuanian broadcaster LRT, as reported by European Pravda
Details: Karis was asked whether he believes Ukraine's accession to NATO is realistic in light of former US President Donald Trump's recent remarks dismissing the idea.
Quote: "It's worth remembering that Estonia began discussing NATO membership when Russian troops were still on our soil, and not everyone believed Estonia, Latvia and Lithuania would ever become NATO members. But here we are – NATO members and allies."
More details: Karis added that both Finland and Sweden have recently joined NATO despite a long history of neutrality.
"Ukraine also needs security guarantees. And in the long term, we are convinced Ukraine will become a NATO member as well," Karis said.
Background:
Estonia plans to allocate over 5% of its GDP to defence needs next year.
Estonian Defence Minister Hanno Pevkur believes NATO countries can realistically raise their defence spending to 5% of GDP within five years.
Read also:
Support Ukrainska Pravda on Patreon!
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
31 minutes ago
- Wall Street Journal
Oil Edges Higher, Supported by Supply-Disruption Concerns
0014 GMT — Oil edges higher in the early Asian session, supported by supply-disruption concerns. President Trump has given Russian President Putin an Aug. 8 deadline to reach a cease-fire with Ukraine, shortening a 50-day deadline he had set. The deadline for Russia to end its invasion and a full cease-fire has aided some worries over supply disruptions, says Janiv Shah, vice president at Rystad Energy, in an email. Front-month WTI crude oil futures are up 0.1% at $69.33/bbl; front-month Brent crude oil futures are 0.1% higher at $71.80/bbl. (
Wall Street Journal
an hour ago
- Wall Street Journal
Trump's Vow to Be ‘President of Peace' Falls Short in Ukraine and Gaza
Since returning to the White House, President Trump has branded himself as the 'president of peace,' boasting that he has averted half a dozen wars and repeatedly saying he deserves the Nobel Peace Prize. Yet six months into his term, his record is decidedly mixed, with scant headway in ending two of the world's most intractable wars, Ukraine and Gaza. Trump has had his successes. He has leveraged economic pressure to tamp down a border clash between Cambodia and Thailand and, his aides say, engaged in intensive telephone diplomacy to avert a war from spiraling between India and Pakistan, two nuclear-armed powers.
Forbes
an hour ago
- Forbes
Restructuring For Nutraceutical Founders Facing Tariffs
WASHINGTON, DC - APRIL 02: U.S. President Donald Trump speaks during a 'Make America Wealthy Again' trade announcement event in the Rose Garden at the White House on April 2, 2025 in Washington, DC. Touting the event as 'Liberation Day', Trump announced additional tariffs targeting goods imported to the U.S. (Photo by) Getty Images The European Union agreed to settle with the United States on a 15% tariff rate to prevent being subject to a 30% or higher rate. Although some categories of goods and services may be exempt or subject to a lower rate, the pharmaceutical and nutraceutical industry anticipates its costs to rise by over $19 billion. While businesses are focused on the import and export rules, along with distribution and manufacturing channels, the underlying impact on the asset valuation and protection of founders and entrepreneurs i among the most impacted industries including, pharmaceuticals, remains to be seen. Over 40% of international exports from Europe are targeted toward the U.S. market. The tariff can dynamically shift business operations and goals for small and medium sized businesses. Additionally, founders and entrepreneurs operating between the two jurisdictions may have to restructure their enterprises and asset holdings to prevent additional tax and tariff exposure. Consider a small family-owned company operating in Germany exporting nutraceutical supplements to the United States in liaison with a sports and fitness company in the United States. With the increased tariff costs, the cost of purchasing supplements for the U.S. company would increase significantly. Additionally, the German company, due to its small size and inability to absorb the increased cost may not be able to meet the prior demands or its contractual obligations. Both the U.S. and the German business owners would be impacted adversely. For founders and entrepreneurs, especially in the wellness, nutraceutical, or pharmaceutical industries, a key component of their value is in their intellectual property. Small companies are often structured for simplicity to minimize administrative burdens on management and compliance. More importantly, the value of the good subject to the tariff duty often includes intellectual property licensing fees which can greatly increase the cost. Founders of small and mid-sized companies in the pharmaceutical industry may need to revisit restructuring their businesses to allow for more licensing and intellectual property access so that manufacturing for domestically distributed goods can be done locally to offset export duties. However, cross-border contractual agreements are not limited to ensuring that licensor and licensee meet the terms of the contact, but also can impact each business' investments, growth, and exit opportunities. Additionally, if the intellectual property is not properly protected, or held within the company manufacturing the product, it may not be protected in the event of a lawsuit against the product manufacturer. A sound structure even for a small business entails separating the intellectual property assets from the primary business activity and implementing a series of licensing and royalty agreements to manage the use of the intellectual property. Business valuations and assets included in a business transaction can be impacted by the structuring of the business. Additionally, segregating the intellectual property may offer tax advantages because it can be placed in more tax-favorable jurisdictions than the tax imposed on income generated by other assets and activities. Overall, the tariff deal between Europe and the United States impacts consumers and business owners in both jurisdictions at multiple levels. Increased costs would shift to the consumers which may make some products unaffordable or inaccessible. The cost of manufacturing and distribution may be unsustainable especially for growing enterprises that are small or mid-sized in the pharmaceutical and nutraceutical industries. Fulfillment orders between companies may be adversely impacted. Business owners, especially with multinational ties, can mitigate some of the burden of the tariffs and maximize their business opportunities by realigning and restructuring to optimize intellectual property access, use, and protection so that manufacturing and distribution in aligned with the consumer needs and location.
